Is twenty-four weeks too short to assess

phoebe-click
Published  · 15 slides · 0 views
↓ Download
Is twenty-four weeks too short to assess
1 / 1
Is twenty-four weeks too short to assess - slide 1 of 15 Is twenty-four weeks too short to assess - slide 2 of 15 Is twenty-four weeks too short to assess - slide 3 of 15 Is twenty-four weeks too short to assess - slide 4 of 15 Is twenty-four weeks too short to assess - slide 5 of 15 Is twenty-four weeks too short to assess - slide 6 of 15 Is twenty-four weeks too short to assess - slide 7 of 15 Is twenty-four weeks too short to assess - slide 8 of 15 Is twenty-four weeks too short to assess - slide 9 of 15 Is twenty-four weeks too short to assess - slide 10 of 15 Is twenty-four weeks too short to assess - slide 11 of 15 Is twenty-four weeks too short to assess - slide 12 of 15 Is twenty-four weeks too short to assess - slide 13 of 15 Is twenty-four weeks too short to assess - slide 14 of 15 Is twenty-four weeks too short to assess - slide 15 of 15
Description
Is twenty-four weeks too short to assess virological success in primary HIV infection treatment ? Anne Vandendriessche1, Thomas Mourez2, Véronique Lemée2, Yasmine Debab1, Gilles Peytavin3, Joël Ladner4, François Caron1, Jean-Christophe

Related Topics

Download this presentation From Below

"Is twenty-four weeks too short to assess" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Presentation Transcript

01
Is twenty-four weeks too short to assess virological success in primary HIV infection treatment ? Anne Vandendriessche1,
Thomas Mourez2, Véronique Lemée2, Yasmine Debab1,
Gilles Peytavin3, Joël Ladner4, François Caron1,
Jean-Christophe Plantier2, Jérémie Leporrier1 1 Infectious Diseases Department, Rouen University Hospital, France
2 Virology Unit, Rouen University Hospital, France
3 Pharmacology and toxicology laboratory, Bichat-Claude Bernard hospital, APHP Paris, France
4 Epidemiology and Public Health Department, Rouen University Hospital, France 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, July 2015<br>
02
Disclosure No conflict of interest to report<br>
03
Background ART in primary HIV-1 infection (PHI)
No randomized clinical trial
Individual and collective benefits1-2
French3, European4 and US guidelines5: treat all PHI

Recommended ART in PHI3-5
Analogy with established infection
Commonly, TDF/FTC + 3rd agent (protease inhibitor)

Goal of ART: « virological success »
Undetectable pVL at week 24 of treatment (W24) 1 Le T. et al. NEJM 2013;368(3):218-30. 2 Cohen MS. et al. NEJM 2011;365(6):493-505. 3 French Guidelines. Rapport Morlat 2013.
4 European AIDS Clinical Society Guidelines, Version 7,1, 2014. 5 Huldrych F. et al. JAMA 2014;312(4):410-425.<br>